Stock TELA TELA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News TELA Bio, Inc.

Equities

TELA

US8723811084

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/07/2024 BST 		5-day change 1st Jan Change
4.49 USD -4.47% Intraday chart for TELA Bio, Inc. -14.48% -32.18%
06-04 TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors CI
05-20 TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
GL
TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors
CI
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
GL
TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer
CI
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating
MT
Earnings Flash (TELA) TELA BIO Posts Q1 Revenue $16.6M, vs. Street Est of $16.3M
MT
Transcript : TELA Bio, Inc., Q1 2024 Earnings Call, May 09, 2024
TELA Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
TELA Bio Reports First Quarter 2024 Financial Results
GL
TELA Bio, Inc. Provides Revenue Guidance for the Year 2024
CI
Morgans rates ARX as Add
AQ
TELA Bio to Announce First Quarter 2024 Financial Results
GL
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR, Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
AQ
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
GL
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR
CI
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
GL
Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating
MT
Transcript : TELA Bio, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $17M, vs. Street Est of $16.4M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TELA Stock
  4. News TELA Bio, Inc.